VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.14%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$204M
AUM Growth
+$15.9M
(+8.5%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
8.1%
Top 10 Holdings %
Top 10 Hldgs %
6.14%
Holding
488
New
66
Increased
245
Reduced
135
Closed
40
Top Buys
| 1 |
CrowdStrike
CRWD
|
$1.1M |
| 2 |
Netflix
NFLX
|
$1.03M |
| 3 |
Qualcomm
QCOM
|
$1.03M |
| 4 |
Royal Caribbean
RCL
|
$1M |
| 5 |
TJX Companies
TJX
|
$973K |
Top Sells
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.11M |
| 2 |
Eli Lilly
LLY
|
$937K |
| 3 |
Freeport-McMoran
FCX
|
$933K |
| 4 |
Align Technology
ALGN
|
$933K |
| 5 |
Martin Marietta Materials
MLM
|
$930K |
Sector Composition
| 1 | Financials | 26.66% |
| 2 | Healthcare | 19.14% |
| 3 | Technology | 17.16% |
| 4 | Energy | 7.21% |
| 5 | Industrials | 6.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Cullinan Oncology
CGEM
$413M
| $72.4K | 0.04% |
4,153
-6,028
| -59% | -$105K |
|
427
Fulcrum Therapeutics
FULC
$414M
| $72K | 0.04% |
+11,606
| New | +$72K |
|
428
Recursion Pharmaceuticals
RXRX
$2.01B
| $71.9K | 0.04% |
9,590
+497
| +5% | +$3.73K |
|
429
Stoke Therapeutics
STOK
$1.13B
| $69.8K | 0.03% |
+5,167
| New | +$69.8K |
|
430
Arcturus Therapeutics
ARCT
$485M
| $69.8K | 0.03% |
2,865
-222
| -7% | -$5.41K |
|
431
Wave Life Sciences
WVE
$1.32B
| $69.7K | 0.03% |
+13,970
| New | +$69.7K |
|
|
AUTL
432
Autolus Therapeutics
AUTL
$389M
| $69.5K | 0.03% |
+19,984
| New | +$69.5K |
|
433
Sana Biotechnology
SANA
$752M
| $69.1K | 0.03% |
12,661
-9,053
| -42% | -$49.4K |
|
434
Structure Therapeutics
GPCR
$1.27B
| $68.8K | 0.03% |
1,753
+273
| +18% | +$10.7K |
|
435
Immunome
IMNM
$916M
| $68.3K | 0.03% |
+5,644
| New | +$68.3K |
|
436
Larimar Therapeutics
LRMR
$337M
| $67.7K | 0.03% |
+9,342
| New | +$67.7K |
|
437
Spyre Therapeutics
SYRE
$1.03B
| $65.8K | 0.03% |
2,797
-3,041
| -52% | -$71.5K |
|
438
ALX Oncology
ALXO
$65.3M
| $64.7K | 0.03% |
10,726
+4,160
| +63% | +$25.1K |
|
439
Prime Medicine
PRME
$663M
| $58.9K | 0.03% |
+11,459
| New | +$58.9K |
|
440
Cassava Sciences
SAVA
$104M
| $56.2K | 0.03% |
4,551
+1,672
| +58% | +$20.6K |
|
441
Cabaletta Bio
CABA
$155M
| $53.9K | 0.03% |
7,207
+2,992
| +71% | +$22.4K |
|
442
Lyell Immunopharma
LYEL
$233M
| $50.7K | 0.02% |
1,748
-397
| -19% | -$11.5K |
|
443
Taysha Gene Therapies
TSHA
$917M
| $48.6K | 0.02% |
+21,709
| New | +$48.6K |
|
444
Kyverna Therapeutics
KYTX
$170M
| $47K | 0.02% |
+6,269
| New | +$47K |
|
445
Zentalis Pharmaceuticals
ZNTL
$126M
| $38.9K | 0.02% |
9,509
+3,719
| +64% | +$15.2K |
|
446
Scilex Holding
SCLX
$159M
| $30.6K | 0.02% |
504
| – | – |
|
|
JBIO
447
Jade Biosciences, Inc. Common Stock
JBIO
$254M
| $6.11K | ﹤0.01% |
+105
| New | +$6.11K |
|
|
BLUE
448
DELISTED
bluebird bio
BLUE
| – | – |
-5,773
| Closed | -$148K |
|
449
Apple
AAPL
$3.56T
| – | – |
-3,881
| Closed | -$666K |
|
450
Analog Devices
ADI
$122B
| – | – |
-3,761
| Closed | -$744K |
|